Ozempic, Wegovy, Mounjaro and Zepbound Pancreatitis: What the Data Show

Short answer

Can Ozempic cause pancreatitis? It can, rarely: acute pancreatitis (inflammation of the pancreas) is a listed warning on every semaglutide and tirzepatide label: Ozempic, Wegovy, Mounjaro and Zepbound. In the trials it was rare, about 0.1 to 0.3 cases per 100 patient-years, and only slightly more common than on placebo or other diabetes drugs. Large studies disagree on whether these drugs raise the risk at all. The main warning sign is severe, persistent stomach pain that may spread to the back, with or without vomiting, and it needs urgent care. Not medical advice. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance. Facts checked October 24, 2026.

Pancreatitis rates on the labels

Each US label (Ozempic, Wegovy, Mounjaro, Zepbound, DailyMed, June to August 2026) reports cases confirmed by an independent committee (adjudicated):

What the labels warn

All four US labels say acute pancreatitis, "including fatal and non-fatal hemorrhagic or necrotizing pancreatitis", has been seen with GLP-1 drugs, and that the drug should be stopped if pancreatitis is suspected. Postmarketing reports for all four list acute and necrotising pancreatitis, sometimes resulting in death. The labels also note that pancreatic enzymes rise on treatment without symptoms: lipase rose on average 22% on Ozempic, 39% on Wegovy and 31% to 42% on Mounjaro, and the clinical meaning of raised enzymes without other signs is unknown. That is why an enzyme result alone does not diagnose pancreatitis.

What large studies found

Trial pooling and real-world studies point in different directions, so the honest summary is that any added risk is small and uncertain.

Why gallstones matter

Gallstones can themselves trigger pancreatitis (gallstone pancreatitis). The Wegovy label notes that substantial or rapid weight loss can increase gallstone risk, and that gallbladder disease was still more common on Wegovy than placebo after accounting for weight lost (gallstones 1.6% vs 0.7% in the weight-loss trials). A 2025 review of 55 trials also found GLP-1 drugs increased gallstones (Chiang 2025) while finding little effect on most other gut events. The Zepbound patient information lists upper stomach pain, fever, yellowing of the skin or eyes and clay-coloured stools as gallbladder warning signs that need prompt care. More: Ozempic and gallbladder problems.

Warning signs

• —Severe stomach pain that does not go away, sometimes spreading to the back.
• —Pain with or without nausea and vomiting.
• —Upper stomach pain with fever, yellow skin or eyes, or clay-coloured stools (gallbladder).
• —Labels say to stop the medicine and get medical care if pancreatitis is suspected. Ordinary early nausea is common and different; ongoing severe pain is not normal.

History of pancreatitis

The patient information for Wegovy, Mounjaro and Zepbound asks people to tell their prescriber if they "have or have had problems with your pancreas" before starting. Whether to use one of these drugs after an episode of pancreatitis is a decision for the prescriber, who will weigh what caused it.

In Canada

The Canadian Ozempic product monograph (July 13, 2026) lists pancreatitis as an uncommon serious side effect. It reports the same diabetes-trial figure (7 vs 3 patients), one case of chronic pancreatitis on Ozempic, and in the 2-year SUSTAIN 6 trial 8 cases on Ozempic vs 10 on placebo (0.27 vs 0.33 per 100 patient-years). The Canadian Wegovy monograph (October 2026) adds the SELECT heart-outcomes trial: 17 cases (0.2%) on Wegovy vs 24 (0.3%) on placebo. Generic semaglutide carries the same warnings; see generic Ozempic in Canada and Ozempic side effects in Canada.

What users report here

None of the 866 live confessions on this site mention pancreatitis (checked October 24, 2026). Stomach complaints that do come up, such as nausea, burping and prolonged vomiting, are covered on sulfur burps and Ozempic and gastroparesis. Stories are not rates.